Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

DOXEPIN 150 MG CAPSULE

Doxepin Hydrochloride
$0.5095per EA

Strength

150 mg/1

Manufacturer

Endo USA Inc.

NDC

49884022203

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

DOXEPIN HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA071422

On Market Since

11/9/1987

Pharmacological Classes

Tricyclic Antidepressant

Price History

1W

0.0%

1M

+2.5%

3M

-6.0%

6M

-0.6%

1Y

+1.6%

3Y

-19.0%

5Y

-28.9%

All

+21.9%

Generic Alternatives

1 alternative • Same active ingredient

DOXEPIN 150 MG CAPSULE
Generic
49884022205•Endo USA Inc.
$0.5095

Related Drugs

Same classification

AMITRIPTYLINE HCL 10 MG TAB
Generic
00781148601•Sandoz Inc.
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
00781148610•Sandoz Inc.
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
16571010501•Rising Pharma Holdings Inc.
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
16571010510•Rising Pharma Holdings Inc.
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
16714025701•NorthStar Rx LLC
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
16714025702•NorthStar Rx LLC
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
16729017101•Accord Healthcare Inc.
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
29300041901•Unichem Pharmaceuticals (USA) Inc.
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
29300041910•Unichem Pharmaceuticals (USA) Inc.
$0.0342
per EA
AMITRIPTYLINE HCL 10 MG TAB
Generic
50268003715•AvPAK
$0.0342
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy